Landscape Analysis of HIV Cure-Related Clinical Trials in 2018
PDF • 2019In August 2018, the Bill & Melinda Gates Foundation contracted TAG to undertake a survey of investigators conducting studies included in our “Research Toward a Cure” clinical trials listing, in order to obtain more detailed information about the current landscape of HIV cure-related clinical research.
A Landscape Analysis of HIV Cure-Related Clinical Trials in 2018
Publication • 2019In August 2018, the Bill & Melinda Gates Foundation contracted TAG to undertake a survey of investigators conducting studies included in our “Research Toward a Cure” clinical trials listing, in order to obtain more detailed information about the current landscape of HIV cure-related clinical research.
Acclaimed American Artist Glenn Ligon Creates Black Rage (back cover) as a Limited Art Edition for Treatment Action Group’s 2019 Research in Action Awards
Statement / Press • 2019Treatment Action Group (TAG) is honored that acclaimed American Artist Glenn Ligon has created and donated a Limited Art Edition entitled Black Rage (back cover) in an edition of 100 prints (and 20 A/Ps) especially for TAG.
TAG Submitted Testimony to the House Committee on Oversight and Reform Hearing on “HIV Prevention Drug: Billions in Corporate Profits After Millions in Taxpayer Investments”
Letters • 2019TAG submitted testimony for the record for the hearing, "HIV Prevention Drug: Billions in Corporate Profits after Millions in Taxpayer Investments" at the request of members of the House Oversight and Reform Committee.
Story: American Gene Technologies HIV Gene Therapy
Page • 2019November 2019 Examples of media coverage: Gene Tech Company Claims to Have Found a Cure for HIV/AIDS – NewNowNext, November 8, 2019 Researchers believe they’ve found the cure for HIV/AIDS – Pink News, November 8, 2019 Research Lab Believes They Have HIV/AIDS Cure – Instinct Magazine, November 7, 2019 American Gene Technologies believes they have the cure for HIV/AIDS – LocalDVM.com, November 6,…Protestors Demand Cepheid Halve the Price of GeneXpert TB Tests to US$5
Statement / Press • 2019The high cost of GeneXpert tests for tuberculosis (TB) leaves open a critical gap in the diagnosis of TB and fails to consider volume of sales and public investments in the development of GeneXpert.
TAG Comment in Response to Proposed Rulemaking: Visas: Ineligibility Based on Public Charge Grounds
Letters • 2019As an organization dedicated to ensuring equitable access to critical health services to individuals and communities affected by HIV/AIDS, tuberculosis (TB), and hepatitis C virus (HCV), Treatment Action Group (TAG) strongly opposes the proposed changes regarding “public charge,” published in the Federal Register on October 11, 2019 (the proposed rule).
Cutting Costs by Including Cheaper ARVs on the New York State Medicaid Preferred Drug List for treatment, PEP, and potentially PrEP
Webinars • 2019On January 17, 2019, Treatment Action Group and Housing Works presented this webinar discussing current advocacy to cut costs by scaling up the use of Mylan’s Cimduo (TDF/3TC) and Symfi (EFV/TDF/3TC) as part of New York State Medicaid. Tim Horn from NASTAD walked webinar participants through the recent FDA approval of Cimduo, Symfi, and Symfi…
Public Comment on USPSTF Draft Recommendations for PrEP and HIV Screening
Letters • 2019The US Preventive Services Task Force (USPSTF) recently released draft recommendations regarding HIV screening for all Americans ages 15-65, including pregnant women, and pre-exposure prophylaxis (PrEP) for individuals highly vulnerable to HIV infection.
2019 Report on TB Research Funding Trends
TB R&D • 2019TAG’s latest report on global funding for TB research and development (R&D), published in collaboration with the Stop TB Partnership, presents new data on TB R&D funding in 2018 and analyzes trends in funding since 2005.